-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $180

Benzinga·07/23/2025 19:07:52
Listen to the news
UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $175 to $180.